Which Follow-Up treatment works best for HER2+ breast cancer? large study aims to find out
NCT ID NCT07540520
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to learn from real-world data to guide future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?